Loading
Diabetes Treatment and Management · Journal article
Frontiers in Endocrinology · August 17, 2026
Encouraging direction, but not yet definitive.
This network meta-analysis of 15 trials (predominantly RCTs) found that GLP-1 receptor agonists reduced apnea-hypopnea index and body mass index versus placebo in overweight or obese patients with moderate-to-severe OSA, but the certainty of evidence was low-to-very-low for most comparisons, and comparisons between active interventions were largely indirect and non-significant. The authors explicitly characterize the treatment hierarchy as hypothesis-generating rather than a basis for firm clinical recommendations.
Network meta-analysis of randomized controlled trials and case-control studies. Overweight or obese patients with moderate-to-severe obstructive sleep apnea; enrolled across 15 studies (13 RCTs, 2 case-control studies). Intervention: SGLT2 inhibitors, GLP-1 receptor agonists, or aerobic exercise. Compared with: Placebo or control; indirect comparisons between active interventions. n = 1,877.
GLP-1 receptor agonists reduced AHI versus placebo by 15.28 events/h (95% CI, −22.22 to −8.35) GLP-1 receptor agonists lowered BMI versus placebo by 1.78 kg/m² (95% CI, −2.15 to −1.41) with moderate certainty GLP-1 receptor agonists improved mean SpO₂ versus placebo by 0.40% (95% CI, 0.25 to 0.55) with low certainty
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
GLP-1 receptor agonists appear to offer benefit for OSA in obese patients, but the low-to-very-low certainty of evidence, lack of high-quality head-to-head comparisons, and non-significant indirect comparisons between active interventions mean these results should not yet guide firm clinical decisions. Larger, higher-quality trials are needed before recommending treatment hierarchy.
A network meta-analysis of 15 trials (mostly RCTs) showing GLP-1 agonists reduce AHI and BMI versus placebo, but confidence is low-to-very-low across most estimates, indirect comparisons are non-significant, and the authors explicitly state findings are hypothesis-generating rather than a basis for firm recommendations.
As stated by the source record.
Quoted from the source exactly as published.
GLP-1 receptor agonists appear to offer benefit for OSA in obese patients, but the low-to-very-low certainty of evidence, lack of high-quality head-to-head comparisons, and non-significant indirect comparisons between active interventions mean these results should not yet guide firm clinical decisions. Larger, higher-quality trials are needed before recommending treatment hierarchy.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Objective Obstructive sleep apnea (OSA) is a highly prevalent sleep disorder strongly linked to obesity and substantially increases the risk of cardiovascular and metabolic diseases. Sodium–glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and aerobic exercise have shown potential in improving OSA through distinct metabolic and physiological mechanisms. However, direct comparative evidence of their efficacy remains limited. This network meta-analysis aimed to compare the effects of SGLT2 inhibitors, GLP-1 receptor agonists, and aerobic exercise on OSA severity in overweight or obese patients. Methods We searched four electronic databases, PubMed, EMBASE, the Cochrane Library, and Web of Science, for articles published before October 31, 2025, without language restrictions. The analysis primarily included randomized controlled trials (RCTs); a limited number of case–control studies were also incorporated due to the scarcity of direct comparative evidence. Primary efficacy outcomes were mean changes in the apnea–hypopnea index (AHI), body mass index (BMI), mean peripheral oxygen saturation (SpO 2 ), and Epworth Sleepiness Scale (ESS) score. The certainty (confidence) of the evidence for every network estimate was appraised with the Confidence in Network Meta-Analysis (CINeMA) framework, which operationalizes the GRADE approach for network meta-analysis. Results A total of 15 studies (13 RCTs and 2 case–control studies) involving 1,877 participants were included in the analysis. GLP-1 receptor agonists demonstrated the greatest reduction in AHI compared with placebo (mean difference [MD] = −15.28 events/h; 95% CI, −22.22 to −8.35). They also showed significant benefit versus placebo in lowering BMI (MD = −1.78 kg/m 2; 95% CI, −2.15 to −1.41) and improving mean SpO 2 (MD = 0.40%; 95% CI, 0.25 to 0.55). Although GLP-1 receptor agonists yielded a statistically significant improvement in ESS score versus placebo (MD = −0.20; 95% CI, −0.26 to −0.14), this effect was an order of magnitude below the 2-point minimal clinically important difference (MCID) for the ESS and is therefore not clinically meaningful. Aerobic exercise ranked highest in surface under the cumulative ranking curve (SUCRA) analysis for this outcome. No network estimate was rated as high certainty. Confidence was moderate for the effect of GLP-1 receptor agonists on BMI, low for their effects on AHI, mean SpO 2, and ESS score versus placebo, and very low for all remaining comparisons, mainly because of within-study bias, imprecision, and suspected reporting bias. Conclusion Compared with placebo, GLP-1 receptor agonists reduced AHI and BMI and improved mean SpO 2, and ranked highest for these outcomes in the SUCRA analysis. Comparisons between the active interventions, however, were largely non-significant and rested on indirect evidence, and the certainty of the evidence was moderate at best, being low or very low for most comparisons. This treatment hierarchy should therefore be regarded as hypothesis-generating rather than as a basis for firm clinical recommendations. Within these limits, these findings suggest that GLP-1 receptor agonists may offer a promising therapeutic approach for managing OSA in overweight or obese patients with metabolic comorbidities, though this remains to be confirmed in larger, high-quality, head-to-head trials.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.